Study Phase 4

Effect on Efficacy, Safety and Quality of Life by Long-Term Treatment of Long-Acting Risperidone Microspheres in Patients With Schizophrenia

  • 1 CSR Summary Not Yet Available
  • 1 NCT00269919
  • 1 Primary Citation Not Available
  • Data Specification Not Available

Trial Information

Generic NameRisperidoneProduct NameRISPERDAL CONSTA®Therapeutic AreaBehaviors and Mental DisordersEnrollment40% Female35.9%% WhiteN/A
Product ClassAtypical AntipsychoticsSponsor Protocol NumberRIS-KOR-64Data PartnerJohnson & JohnsonCondition StudiedSchizophreniaMean/Median Age (Years)35

Supporting Documentation

Additional Information

Please note: individual participant-level data are not available for this trial. Only the synoptic report is available.

Approved Data Requests Associated with this Trial

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.